Please Wait.....
Report
Stem Cell and Regenerative Therapy: Global Markets
Market Research Report I 2026-02-09 I 168 Pages I BCC Research
Description
Report Scope
The report provides an overview of the global stem cell and regenerative therapy market and analyzes market trends. The report includes global revenue (in $ millions) for the base year data (2024) and estimated data for the forecast period (2025 through 2030). The market is segmented by product and services, application and region. The regions covered in this study include North America, Europe, Asia-Pacific and the Rest of the World, with a focus on major countries in each region.
The report focuses on significant trends and challenges that affect the market and vendor landscape. It analyzes environmental, social and corporate governance (ESG) developments and discusses emerging technologies and the patent landscape related to the market.
The report concludes with an analysis of the competitive landscape, which provides the ranking or share of key companies in the global stem cell and regenerative medicine market, as well as a patent analysis. It also features a section with company profiles that provides overviews, key financials, product portfolios and recent developments of key market companies.
Report Includes
- 50 data tables and 62 additional tables
- Overview and an analysis of the global market for stem cell and regenerative therapy (medicines)
- Analyses of the global market trends, with historic revenue data from 2022 to 2024, estimates for 2025 and projections of CAGRs through 2030
- Estimates of the current market size and revenue prospects of the global market, along with a corresponding market share analysis based on product and service type, application and region
- Facts and figures pertaining to global market dynamics, advancements in therapy, regulations, prospects and the impact of macroeconomic factors
- Insights derived from Porter's Five Forces model, as well as global supply chain and PESTLE analyses
- Patent review, featuring key granted and published patents
- Review of emerging trends and technologies as well as new developments in the stem cell and regenerative therapy market
- Analysis of the industry structure, including companies' market shares and rankings, strategic initiatives and venture fundings, and an investment outlook
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
- Profiles of the leading companies, including Gilead Sciences Inc., Novartis AG, Bristol-Myers Squibb Co., Organogenesis Inc., and MiMedx Group Inc.
Executive Summary
Summary:
The global market for stem cell and regenerative therapy is projected to grow from an estimated $16.7 billion in 2025 to $43.8 billion by 2030, at a compound annual growth rate (CAGR) of 21.3% from 2025 to 2030.
Regenerative therapy employs cells, tissues or genetic material to replace, repair or regenerate damaged tissues or organs. Many chronic, fatal and difficult-to-treat illnesses such as cancer, Parkinson's disease, Alzheimer's disease, diabetes, kidney and cardiovascular diseases can be treated and potentially cured with regenerative therapy. Stem cell therapy is one of the most promising forms of medical treatment. Stem cells are being widely adopted across numerous applications, including neurological disorders, orthopedic treatments, oncology, diabetes, injuries and wounds, cardiovascular issues and more. Private organizations and governments in many countries recognize the benefits of stem cell therapies, leading to significant investments in stem cell research.
Private companies are investing in technological advances and optimizing cell culture technology to boost the production of low-cost therapeutics to meet growing demand for the treatment and prevention of chronic diseases. Technological advances focus on improving the stem cell culture process, which helps limit the overall cost of treatment and makes research easier for those using stem cell culture technology in their life science research. Advances have been made in stem cell culture media formulations, culture systems and equipment used in the development and processing of stem cells.
Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Market Growth Factors
Emerging Technologies
Segmental Analysis
Regional Analysis
Conclusion
Chapter 2 Market Overview
Technology Background
Stem Cell
Embryonic Stem Cells
Adult Stem Cells
Mesenchymal Stem Cells
Hematopoietic Stem Cells
Neural Stem Cell
Endothelial Progenitor Cell
Epithelial Stem Cell
Very Small Embryonic-Like Cell
Cord Blood Stem Cell
Induced Pluripotent Stem Cells
Cell Therapy
A Brief History of CAR-T Cell Therapy
FDA Product Approvals
Gene Therapy
Evolution of Gene Therapy
Macroeconomic Factors Analysis
PESTEL Analysis
Impact of U.S. Tariff Laws on the Stem Cell and Regenerative Therapy Market
Porter's Five Forces Analysis
Potential for New Entrants (Moderate to High)
Bargaining Power of Suppliers (Moderate to High)
Bargaining Power of Buyers (High)
Threat of Substitutes (Low to Moderate)
Competition in the Industry (High)
Chapter 3 Market Dynamics
Market Dynamics
Market Drivers
Growing Demand for Regenerative Medicines
Increasing Research and Regulatory Approval for Tissue Engineering Products
Rising Venture Capital Funding
Demand for an Effective Drug Discovery and Development Process
Rising Focus on Minimizing Animal Testing
Market Restraints
High Cost and Lack of Skilled Workforce
Complex Regulatory Framework
Market Opportunities
Technological Advances
Growth in iPSC Banking
Chapter 4 Regulatory Landscape
Overview
Gene Therapy Regulations
Cell Therapy Regulations
Viral and Non-Viral Vectors
Media
Regulatory Frameworks in the U.S.
Regulatory Frameworks in Europe
Cell and Gene Therapy Regulations in Europe
Regulatory Frameworks in Asia-Pacific
Chapter 5 Emerging Technologies and New Developments
Overview
Reprogramming Technologies
Gene Editing Technologies
3D Organoids
Artificial Intelligence in Stem Cell Research
Chapter 6 Market Segment Analysis
Segmentation Breakdown
Market Breakdown by Products and Services
Key Takeaways
Therapeutics
Tools and Reagents
Cell Banking
Market Breakdown by Application
Key Takeaways
Oncology
Orthopedic
Diabetes
Dermatology
Cardiovascular Disorders
Central Nervous System Disorders
Others
Geographic Breakdown
Market Breakdown by Region
Key Takeaways
North America
Europe
Asia-Pacific
Rest of the World
Chapter 7 Competitive Intelligence
Key Takeaways
Leading Players in the CGT Market, 2024
Leading Players in the Tissue Engineering Market, 2024
Strategic Analysis
Chapter 8 Sustainability in the Stem Cell and Regenerative Therapy Market: ESG Perspective
Sustainability: The Stem Cell and Regenerative Therapy Market
Understanding the ESG Data
Key ESG Issues
Environmental Performance
Social Performance
Governance Performance
Concluding Remarks from BCC
Chapter 9 Patent Landscape
Key Takeaways
Patent Review
Gene Therapy Patents, by Year
Gene Therapy Patents, by Leading Applicants
Gene Therapy Patents, by Document Type
Cell Therapy Patents, by Year
Cell Therapy Patents, by Leading Applicants
Cell Therapy Patents, by Status
Tissue Engineering Patents, by Year
Tissue Engineering Patents, by Leading Applicants
Tissue Engineering Patents, by Status
Chapter 10 Appendix
Methodology
Abbreviations
References
Company Profiles
ABBVIE INC.
AMGEN INC.
BIOGEN
BLUEBIRD BIO INC. (GENETIX BIOTHERAPEUTICS INC.)
BRISTOL-MYERS SQUIBB CO.
CELLECTIS S.A.
CRISPR THERAPEUTICS
EUREKA THERAPEUTICS INC.
GILEAD SCIENCES INC.
MIMEDX GROUP INC.
NOVARTIS AG
ORGANOGENESIS INC.
STRYKER
TECNOSS
ZIMMER BIOMET
List of Tables
Summary Table : Global Market for Stem Cell and Regenerative Therapy, by Region, Through 2030
Table 1 : U.S. FDA-Approved CAR-T Cell Therapies
Table 2 : Tissue Engineering and Regeneration: Venture Capital Funding, 2024
Table 3 : Tissue Engineering and Regeneration: Pricing
Table 4 : Tissue Engineering and Regeneration: Regulatory Overview, 2025
Table 5 : Brief Information on iPSC Repositories
Table 6 : Asia-Pacific: Regulatory Landscape, 2024
Table 7 : Global Market for Stem Cell and Regenerative Therapy, by Products and Services, Through 2030
Table 8 : Global Market for Stem Cell and Regenerative Therapy for Therapeutics, by Product Type, Through 2030
Table 9 : Global Market for Stem Cell and Regenerative Therapy for Therapeutics, by Region, Through 2030
Table 10 : Global Market for Stem Cell and Regenerative Therapy for Cell Therapy, by Region, Through 2030
Table 11 : FDA-Approved Cell-Based Immunotherapy Products
Table 12 : Approved Human Gene Therapy Products
Table 13 : Global Market for Stem Cell and Regenerative Therapy for Gene Therapy, by Region, Through 2030
Table 14 : Global Market for Stem Cell and Regenerative Therapy for Tissue Engineering, by Region, Through 2030
Table 15 : Recently Launched Stem Cell Reagents, 2024 and 2025
Table 16 : Global Market for Stem Cell and Regenerative Therapy for Tools and Reagents, by Region, Through 2030
Table 17 : Global Market for Stem Cell and Regenerative Therapy for Cell Banking, by Region, Through 2030
Table 18 : Global Market for Stem Cell and Regenerative Therapy, by Application, Through 2030
Table 19 : Global Market for Stem Cell and Regenerative Therapies for Oncology, by Region, Through 2030
Table 20 : Orthopedics and Musculoskeletal Disorders: Tissue Engineeringand Regeneration Product
Table 21 : Global Market for Stem Cell and Regenerative Therapy for Orthopedics, by Region, Through 2030
Table 22 : Global Market for Stem Cell and Regenerative Therapy for Diabetes, by Region, Through 2030
Table 23 : Dermatology: Tissue Engineering and Regeneration Products
Table 24 : Global Market for Stem Cell and Regenerative Therapy for Dermatology, by Region, Through 2030
Table 25 : Global Market for Stem Cell and Regenerative Therapy for CVDs, by Region, Through 2030
Table 26 : Global Market for Stem Cell and Regenerative Therapy for Central Nervous System Disorders, by Region, Through 2030
Table 27 : Global Market for Stem Cell and Regenerative Therapy for Other Applications, by Region, Through 2030
Table 28 : Global Market for Stem Cell and Regenerative Therapy, by Region, Through 2030
Table 29 : North American Market for Stem Cell and Regenerative Therapy, by Products and Services, Through 2030
Table 30 : North American Market for Stem Cell and Regenerative Therapy for Therapeutics, by Product Type, Through 2030
Table 31 : North American Market for Stem Cell and Regenerative Therapy, by Application, Through 2030
Table 32 : North American Market for Stem Cell and Regenerative Therapy, by Country, Through 2030
Table 33 : European Market for Stem Cell and Regenerative Therapy, by Products and Services, Through 2030
Table 34 : European Market for Stem Cell and Regenerative Therapy for Therapeutics, by Product Type, Through 2030
Table 35 : European Market for Stem Cell and Regenerative Therapy, by Application, Through 2030
Table 36 : European Market for Stem Cell and Regenerative Therapy, by Country, Through 2030
Table 37 : Asia-Pacific Market for Stem Cell and Regenerative Therapy, by Products and Services, Through 2030
Table 38 : Asia-Pacific Market for Stem Cell and Regenerative Therapy for Therapeutics, by Product Type, Through 2030
Table 39 : Asia-Pacific Market for Stem Cell and Regenerative Therapy, by Application, Through 2030
Table 40 : Asia-Pacific Market for Stem Cell and Regenerative Therapy, by Country, Through 2030
Table 41 : RoW Market for Stem Cell and Regenerative Therapy, by Products and Services, Through 2030
Table 42 : RoW Market for Stem Cell and Regenerative Therapy for Therapeutics, by Product Type, Through 2030
Table 43 : RoW Market for Stem Cell and Regenerative Therapy, by Application, Through 2030
Table 44 : Leading Players, by Ranking, 2024
Table 45 : Leading Players, by Rank, 2024
Table 46 : Recent Developments in the Stem Cell and Regenerative Therapy Market, 2023-2025
Table 47 : ESG Rankings for Major Stem Cell and Regenerative Therapy Companies, 2025*
Table 48 : ESG: Environmental Overview
Table 49 : ESG: Social Overview
Table 50 : ESG: Governance Overview
Table 51 : Patent Applications Related to Gene Therapy, by Applicant, 2020-2025
Table 52 : Select Patent Grants for Gene Therapy, 2024 and 2025
Table 53 : Patent Applications Related to Cell Therapy, by Applicant, 2020-2025
Table 54 : Select Patents Granted for Cell Therapy, 2024 and 2025
Table 55 : Patent Applications for Tissue Engineering, by Applicant, 2020-2025
Table 56 : Select Patents Granted for Tissue Engineering, 2024 and 2025
Table 57 : Abbreviations Used in the Stem Cell and Regenerative Therapy Market Report
Table 58 : AbbVie Inc.: Company Snapshot
Table 59 : AbbVie Inc.: Financial Performance, FY 2023 and 2024
Table 60 : AbbVie Inc.: Product Portfolio
Table 61 : AbbVie Inc.: News/Key Developments, 2023-2025
Table 62 : Amgen Inc.: Company Snapshot
Table 63 : Amgen Inc.: Financial Performance, FY 2023 and 2024
Table 64 : Amgen Inc.: Product Portfolio
Table 65 : Amgen Inc.: News/Key Developments, 2024
Table 66 : Biogen: Company Snapshot
Table 67 : Biogen: Financial Performance, FY 2023 and 2024
Table 68 : Biogen: Product Portfolio
Table 69 : Bluebird Bio Inc. (Genetix Biotherapeutics Inc.): Company Snapshot
Table 70 : Bluebird Bio Inc. (Genetix Biotherapeutics Inc.): Financial Performance, FY 2023 and 2024
Table 71 : Bluebird Bio Inc. (Genetix Biotherapeutics Inc.): Product Portfolio
Table 72 : Bluebird Bio Inc. (Genetix Biotherapeutics Inc.): News/Key Developments, 2022-2025
Table 73 : Bristol-Myers Squibb Co.: Company Snapshot
Table 74 : Bristol-Myers Squibb Co.: Financial Performance, FY 2023 and 2024
Table 75 : Bristol-Myers Squibb Co.: Product Portfolio
Table 76 : Bristol-Myers Squibb Co.: News/Key Developments, 2023-2025
Table 77 : Cellectis S.A.: Company Snapshot
Table 78 : Cellectis S.A.: Financial Performance, FY 2023 and 2024
Table 79 : Cellectis S.A.: Product Portfolio
Table 80 : Cellectis S.A.: News/Key Developments, 2023 and 2024
Table 81 : CRISPR Therapeutics: Company Snapshot
Table 82 : CRISPR Therapeutics: Financial Performance, FY 2023 and 2024
Table 83 : CRISPR Therapeutics: Product Portfolio
Table 84 : CRISPR Therapeutics: News/Key Developments, 2023 and 2024
Table 85 : Eureka Therapeutics Inc.: Company Snapshot
Table 86 : Eureka Therapeutics Inc: Product Portfolio
Table 87 : Eureka Therapeutics Inc.: News/Key Developments, 2023 and 2024
Table 88 : Gilead Sciences Inc.: Company Snapshot
Table 89 : Gilead Sciences Inc.: Financial Performance, FY 2023 and 2024
Table 90 : Gilead Sciences Inc.: Product Portfolio
Table 91 : Gilead Sciences Inc.: News/Key Developments, 2022-2025
Table 92 : MiMedx Group Inc.: Company Snapshot
Table 93 : MiMedx Group Inc.: Financial Performance, FY 2023 and 2024
Table 94 : MiMedx Group Inc.: Product Portfolio
Table 95 : MiMedx Group Inc.: News/Key Developments, 2022-2024
Table 96 : Novartis AG: Company Snapshot
Table 97 : Novartis AG: Financial Performance, FY 2023 and 2024
Table 98 : Novartis AG: Product Portfolio
Table 99 : Novartis AG: News/Key Developments, 2023 and 2024
Table 100 : Organogenesis Inc.: Company Snapshot
Table 101 : Organogenesis Inc.: Financial Performance, FY 2023 and 2024
Table 102 : Organogenesis Inc.: Product Portfolio
Table 103 : Stryker: Company Snapshot
Table 104 : Stryker: Financial Performance, FY 2023 and 2024
Table 105 : Stryker: Product Portfolio
Table 106 : Stryker: News/Key Developments, 2025
Table 107 : Tecnoss: Company Snapshot
Table 108 : Tecnoss: Product Portfolio
Table 109 : Zimmer Biomet: Company Snapshot
Table 110 : Zimmer Biomet: Financial Performance, FY 2023 and 2024
Table 111 : Zimmer Biomet: Product Portfolio
List of Figures
Summary Figure : Global Market Shares for Stem Cell and Regenerative Therapy, by Region, 2024
Figure 1 : Historical Development of CAR T-Cell Therapy
Figure 2 : PESTEL Analysis: Stem Cell and Regenerative Therapy Market
Figure 3 : Porter's Five Forces Analysis: Stem Cell and Regenerative Therapy Market
Figure 4 : Market Dynamics of Stem Cell and Regenerative Therapy
Figure 5 : Number of Scientific Publications on Tissue Engineering, by Year, 2021-2024
Figure 6 : Phases of the R&D Process
Figure 7 : Emerging Technologies in the Stem Cell and Regenerative Therapy Market
Figure 8 : Global Market Shares for Stem Cell and Regenerative Therapy, by Products and Services, 2024
Figure 9 : Global Market Shares for Stem Cell and Regenerative Therapy for Therapeutics, by Product Type, 2024
Figure 10 : Global Market Shares for Stem Cell and Regenerative Therapy, by Application, 2024
Figure 11 : T-Cell Therapy Technique
Figure 12 : Cancer Stem Cell Market, by Type of Cancer
Figure 13 : Global Market Shares for Stem Cell and Regenerative Therapy, by Region, 2024
Figure 14 : North American Market Shares for Stem Cell and Regenerative Therapy, by Country, 2024
Figure 15 : U.S. Elderly Population (65 and Older), 2010-2050
Figure 16 : European Market Shares for Stem Cell and Regenerative Therapy, by Country, 2024
Figure 17 : Asia-Pacific Market Shares for Stem Cell and Regenerative Therapy, by Country, 2024
Figure 18 : How a Strong ESG Proposition Benefits Businesses
Figure 19 : ESG Pillars
Figure 20 : Patents Granted Related to Gene Therapy, by Year, 2020-2025
Figure 21 : Patent Shares for Gene Therapy Technology, by Document Type, 2020-2025
Figure 22 : Patents Granted Related to Cell Therapy, by Year, 2020-2025
Figure 23 : Patent Shares for Cell Therapy Technology, by Application Status, 2020-2025
Figure 24 : Patents Granted Related to Tissue Engineering, by Year, 2020-2025
Figure 25 : Patents Shares for Tissue Engineering, by Application Status, 2020-2025
Figure 26 : AbbVie Inc.: Revenue Share, by Business Unit, FY 2024
Figure 27 : AbbVie Inc.: Revenue Share, by Region/Country, FY 2024
Figure 28 : Amgen Inc.: Revenue Share, by Business Unit, FY 2024
Figure 29 : Amgen Inc.: Revenue Share, by Region/Country, FY 2024
Figure 30 : Biogen: Revenue Share, by Business Unit, FY 2024
Figure 31 : Biogen: Revenue Share, by Country/Region, FY 2024
Figure 32 : Bristol-Myers Squibb Co.: Revenue Share, by Business Unit, FY 2024
Figure 33 : Bristol-Myers Squibb Co.: Revenue Share, by Country/Region, FY 2024
Figure 34 : Gilead Sciences Inc.: Revenue Share, by Business Unit, FY 2024
Figure 35 : Gilead Sciences Inc.: Revenue Share, by Country/Region, FY 2024
Figure 36 : MiMedx Group Inc.: Revenue Share, by Business Unit, FY 2024
Figure 37 : Novartis AG: Revenue Share, by Business Unit, FY 2024
Figure 38 : Novartis AG: Revenue Share, by Country/Region, FY 2024
Figure 39 : Organogenesis Inc.: Revenue Share, by Business Unit, FY 2024
Figure 40 : Stryker: Revenue Share, by Business Unit, FY 2024
Figure 41 : Stryker: Revenue Share, by Country/Region, FY 2024
Figure 42 : Zimmer Biomet: Revenue Share, by Business Unit, FY 2024
Figure 43 : Zimmer Biomet: Revenue Share, by Country/Region, FY 2024
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security